Moderate-to-severe allergic rhinitis Rhinitis, Allergic
Conditions
Interventions
Participants will receive intranasal fluticasone furoate 110 mcg/day combined with a matching oral placebo for the first 2 weeks, followed by intranasal fluticasone furoate alone until the end of the
Intranasal corticosteroid (fluticasone furoate) plus placebo,Intranasal corticosteroid (fluticasone furoate) plus desloratadine 10 mg,Intranasal corticosteroid (fluticasone furoate) plus desloratadine
Sponsors
Faculty of Medicine Vajira Hospital, Navamindradhiraj University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1 Adults aged over 18 years. 2 Diagnosed with moderate to severe allergic rhinitis based on ARIA guideline (VAS >= 5) (confirmed by a positive skin prick test or serum specific IgE) 3 Unresponsive to INCS alone after a minimum of 2 weeks of treatment. 4 Able to provide informed consent.
Exclusion criteria
Exclusion criteria: 1 History of sinus surgery or turbinate surgery 2 Pregnant or breastfeeding women. 3 Presence of autoimmune diseases. 4 Patients with a history of hypersensitivity to desloratadine or corticosteroids. - Presence of nasal polyps or other structural nasal abnormalities such as septal deviation - Concurrent respiratory infections
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in Total Nasal Symptom Score (TNSS) from baseline Baseline and Week 4 TNSS nasal obstruction nasal discharge sneezing and nasal itching each symptom scored 0 to 3 total score 0 to 12 | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in Rcq36, VAS, ESS Baseline and Week 4 Rcq36, VAS, ESS | — |
Countries
Thailand
Contacts
Public Contactnathnicha kittipibul
vajira hsopital
Outcome results
None listed